View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 23, 2019updated 12 Jul 2022 12:23pm

Trial finds depression drug sertraline reduces anxiety first

A new clinical trial led by University College London (UCL) has found that common antidepressant sertraline causes a decrease in anxiety weeks before relieving depressive symptoms.

A new clinical trial led by University College London (UCL) has found that common antidepressant sertraline causes a decrease in anxiety weeks before relieving depressive symptoms.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The placebo-controlled study was conducted in 653 patients in England displaying mild to moderate symptoms of depression and anxiety.

The trial was funded by the National Institute for Health Research (NIHR).

In addition to UCL Psychiatry, the trial was performed at the Universities of Bristol, Liverpool, and York.

Sertraline belongs to a common class of antidepressants known as selective serotonin reuptake inhibitors (SSRI).

At six weeks, the drug had not shown any evidence of improvement in depressive symptoms such as low mood, loss of pleasure and poor concentration.

Researchers described the evidence observed by week 12 of the study as ‘weak’.

The findings revealed that more patients treated with the drug had an overall improvement in mental health compared to those on placebo, indicating a potential clinically meaningful treatment effect.

UCL Psychiatry researcher and study lead author Dr Gemma Lewis said: “It appears that people taking the drug are feeling less anxious, so they feel better overall, even if their depressive symptoms were less affected.

“We hope that we have cast new light on how antidepressants work, as they may be primarily affecting anxiety symptoms such as nervousness, worry and tension, and taking longer to affect depressive symptoms.”

Study participants were reported to be more representative of the patients currently receiving antidepressants in the UK compared to prior studies.

Around 54% of participants met commonly-used depression criteria, while the remaining 46% met the generalised anxiety criteria.

Patients received sertraline or placebo for 12 weeks as part of the trial. Data revealed no clinically meaningful decrease in depressive symptoms after six weeks, the primary outcome of the trial.

Investigators found strong evidence that the drug mitigated generalised anxiety symptoms. The improvement is said to have retained from six to 12 weeks, resulting in a better mental health-related quality of life.

UCL Psychiatry division head professor Glyn Lewis said: “Our study supports the current use of antidepressants and finds that sertraline is effective for the people likely to receive antidepressants in primary care. They work, just in a different way than we had expected.”

Findings from the trial have been published in The Lancet Psychiatry journal.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena